Research progress of empagliflozin in the treatment of type 2 diabe-tes mellitus and cardiovascular and renal benefits
10.12092/j.issn.1009-2501.2025.03.015
- VernacularTitle:恩格列净治疗2型糖尿病和心肾获益的研究进展
- Author:
Zihan LIU
1
;
Wenyu DU
;
Caihui GUO
;
Zhi WANG
;
Ying LI
;
Zhanjun DONG
Author Information
1. 河北医科大学研究生学院,石家庄 050017,河北;河北省人民医院药学部,河北省临床药学重点实验室,石家庄 050051,河北
- Publication Type:Journal Article
- Keywords:
empagliflozin;
type 2 diabetes melli-tus;
heart failure;
chronic kidney disease
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(3):412-418
- CountryChina
- Language:Chinese
-
Abstract:
Type 2 diabetes mellitus(T2DM)is an insulin resistance disease.Improving insulin resis-tance and controlling blood glucose are the main means of clinical treatment for T2DM.Empa-gliflozin is a highly selective sodium-dependent glu-cose transporters(SGLT)2 inhibitor,which is inde-pendent of insulin.It can effectively control blood glucose levels,reduce blood pressure and body weight,protect heart and kidney function,reduce the rehospitalization rate and the risk of death in patients with heart failure(HF),and does not in-crease the risk of hypoglycemia.Empagliflozin can be used alone or in combination with other hypo-glycemic drugs to control blood glucose.This arti-cle reviews the mechanism of action,clinical bene-fits,and combination with other drugs of empa-gliflozin,aiming to provide reference for the clinical use of empagliflozin.
